IFNB1 and myeloid sarcoma: Owing to the anti-inflammatory and immunomodulatory properties of hADSCs, they can be a good source for stem cell-based gene therapy in MS disorders35,37 MS is a chronic inflammatory disease requiring long-term treatment, and IFN-β is currently used as the first-line treatment for MS38.